Recent News

• 12.09.2025 - Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection
• 11.20.2025 - Lucid Diagnostics Named a GenomeWeb 2025 Best Places to Work Top-Ranking Honoree
• 11.13.2025 - Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
• 10.29.2025 - Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 12, 2025
• 10.15.2025 - Lucid Diagnostics to Participate in the 2025 Maxim Growth Summit
• 09.25.2025 - Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors
• 09.16.2025 - Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs
• 09.11.2025 - Lucid Diagnostics Announces Closing of Public Offering of Common Stock
• 09.10.2025 - Lucid Diagnostics Announces Pricing of Public Offering of Common Stock

Recent Filings

• 12.05.2025 - S-3 Registration statement under Securities Act of 1933
• 11.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.12.2025 - EX-99.1 EX-99.1
• 11.12.2025 - 8-K Current report
• 10.10.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 10.07.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.07.2025 - 3 Initial statement of beneficial ownership of securities
• 09.25.2025 - 8-K Current report
• 09.25.2025 - EX-99.1 EX-99.1
• 09.11.2025 - EX-99.1 EX-99.1